Global Radiotherapy Market - 2025-2033

Radiotherapy Market Size

The global radiotherapy market was valued at US$ 6.17 Billion in 2023. The market size reached US$ 6.48 Billion in 2024 and is expected to reach US$ 10.56 Billion by 2033, growing at a CAGR of 5.6% during the forecast period 2025-2033.

Radiotherapy Market Overview

Radiotherapy is a vital cancer treatment modality that uses high-energy radiation, such as X-rays, gamma rays, or proton beams, to destroy cancer cells or inhibit their growth. It can be administered externally through external beam radiation therapy (EBRT) or internally via brachytherapy.

The radiotherapy market is being driven by several key factors, including the rising global prevalence of cancer, growing awareness of radiotherapy's effectiveness, advancements in treatment technology, and increasing investment in healthcare infrastructure. Opportunities lie in the continued development of more precise and less toxic radiation techniques, integration of artificial intelligence for treatment planning, and expanding access in emerging markets.

North America currently dominates the radiotherapy market due to its high cancer burden, advanced healthcare systems, and early adoption of cutting-edge technology. Meanwhile, the Asia-Pacific region is the fastest-growing, driven by rapidly increasing cancer rates, government-led healthcare expansion, improved access to advanced treatments, and a surge in regional investments and collaborations in the medical technology sector.

Radiotherapy Market Dynamics: Drivers & Restraints

Drivers:

Rising prevalence of cancers is significantly driving the radiotherapy market growth

The rising prevalence of cancers worldwide is a key driver of growth in the radiotherapy market. As cancer cases continue to increase due to factors such as aging populations, lifestyle-related risks, and improved diagnostic techniques, the demand for effective and accessible treatment options has intensified. For instance, according to the International Agency for Research on Cancer, it is stated that around 20 million cancer cases were incident, and it is estimated that around 32.6 million new cancer cases will be reported.

Radiotherapy plays a vital role in cancer management, either as a standalone therapy or in combination with surgery and chemotherapy. Its ability to precisely target and destroy cancer cells while preserving surrounding healthy tissue makes it a preferred choice across various cancer types. This growing patient pool, coupled with advancements in radiotherapy technology, is expected to propel market expansion significantly in the coming years.

The increasing technological advancements are expected to boost the radiotherapy market

Increasing technological advancements are expected to significantly boost the radiotherapy market by enhancing treatment precision, efficiency, and patient outcomes. Innovations such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic body radiation therapy (SBRT), and proton beam therapy have revolutionized cancer treatment by allowing higher radiation doses to be delivered directly to tumors while minimizing damage to surrounding healthy tissue. These advanced techniques reduce side effects and improve recovery times, making radiotherapy a more attractive option for both patients and healthcare providers.

For instance, in May 2025, GE HealthCare announced plans to expand its radiation oncology portfolio and unveiled its new AI-powered MR Contour DL at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2025 Congress in Vienna, Austria. The company also highlighted advancements in its Intelligent Radiation Therapy (iRT) software, designed to streamline complex workflows, reduce the time from diagnosis to treatment, and deliver more precise radiation therapy.

Additionally, the integration of artificial intelligence (AI), machine learning, and real-time imaging in treatment planning and delivery is further optimizing accuracy and personalization of care. As these technologies become more widely available and cost-effective, their adoption is expected to accelerate globally, driving growth and expanding the scope of radiotherapy in cancer management.

Restraint:

The high device and treatment costs are hampering the growth of the radiotherapy market

High device and treatment costs are expected to hinder the growth of the radiotherapy market, particularly in low- and middle-income regions. Advanced radiotherapy equipment such as linear accelerators, proton therapy systems, and stereotactic radiotherapy machines requires substantial capital investment, ongoing maintenance, and specialized infrastructure. Additionally, the cost of treatment itself can be financially burdensome for patients without comprehensive insurance coverage.

Opportunity:

The expansion into emerging regions is expected to create a lucrative opportunity for the radiotherapy market

The expansion into emerging regions is expected to create a lucrative opportunity for the radiotherapy market due to a combination of rising cancer incidence, improving healthcare infrastructure, and growing government support. Countries in Asia-Pacific, Latin America, the Middle East, and parts of Africa are experiencing a surge in cancer diagnoses, driven by aging populations, lifestyle changes, and better screening programs.

At the same time, these regions are increasingly investing in healthcare modernization, including the development of cancer care centers and the procurement of advanced radiotherapy equipment. International manufacturers are also forming partnerships and establishing local production facilities to reduce costs and improve access.

Radiotherapy Market, Segment Analysis

The global radiotherapy market is segmented based on type, technology, product type, form, end-user, and region.

The external beam radiation therapy from the type segment is expected to hold 38.04% of the market share in 2024 in the radiotherapy market

The external beam radiation therapy (EBRT) segment is expected to dominate the radiotherapy market due to its widespread use, technological advancements, and clinical effectiveness across a broad range of cancers. EBRT is a non-invasive technique that delivers high-energy radiation precisely to tumor sites while minimizing damage to surrounding healthy tissue.

It is commonly used in the treatment of cancers such as breast, prostate, lung, and head and neck, making it the most versatile and widely applicable form of radiotherapy. The growing adoption of advanced EBRT techniques has further improved treatment accuracy and outcomes. Additionally, its relative affordability compared to other forms like proton therapy contributes to its dominant position in both developed and emerging markets.

Radiotherapy Market, Geographical Analysis

North America is expected to dominate the global radiotherapy market with a 40.2% share in 2024

North America is likely to dominate the radiotherapy market for a variety of factors, including high cancer prevalence, a strong healthcare infrastructure, technological breakthroughs, and advantageous reimbursement policies. The region reports a large number of cancer cases each year, particularly prostate, breast, and lung cancers, which increases the demand for effective treatment options such as radiotherapy. According to the International Agency for Research on Cancer, approximately 2.67 million new cancer cases were reported, and the number of new cancer cases is expected to increase by 3.83 million by 2045.

Furthermore, North America benefits from the early adoption of modern radiotherapy methods like image-guided radiotherapy (IGRT), proton therapy, and stereotactic body radiotherapy (SBRT). Leading market companies, ongoing R&D investment, and government backing through initiatives such as the Cancer Moonshot program all help to drive innovation and accessibility in therapy. Well-established healthcare facilities and a wide range of experienced specialists improve treatment outcomes and patient confidence. Furthermore, robust insurance coverage and reimbursement arrangements, particularly in the United States and Canada, lessen patients' financial burden, making radiotherapy more accessible.

Asia-Pacific is growing at the fastest pace in the radiotherapy market holding 21.8% of the market share

Asia-Pacific is projected to be the fastest-growing region in the radiotherapy market, driven by a sharp rise in cancer incidence, increased healthcare investments, and rapid adoption of advanced technologies. With populations aging and lifestyle-related risk factors becoming more prevalent, the region is experiencing a surge in cancer diagnoses, prompting governments and private sectors to expand oncology infrastructure. Countries like China, India, and Japan are investing heavily in radiotherapy equipment and workforce development under national health initiatives.

Radiotherapy Market Competitive Landscape

Top companies in the radiotherapy market include Accuracy Incorporated, Varian, Elekta AB, IBA (Ion Beam Applications), Mevion Medical Systems, Inc., GE Healthcare, Hitachi, Ltd., Canon Inc., ViewRay Systems, Inc., among others.

Radiotherapy Market, Key Developments

• In January 2025, RefleXion Medical announced the launch of the BIOGUIDE-X2 clinical study. The study aims to expand the clinical indications for SCINTIX biology-guided radiotherapy and is being conducted at Hackensack Meridian John Theurer Cancer Center, in collaboration with Georgetown’s Lombardi Comprehensive Cancer Center, an NCI-designated comprehensive cancer center.

• In September 2024, RefleXion Medical, Inc. announced that Smilow Cancer Hospital had successfully delivered the world’s first radiotherapy treatment plan that integrates multiple radiotherapy modalities for a patient with metastatic cancer.

The global radiotherapy market report delivers a detailed analysis with 70+ key tables, more than 75+ visually impactful figures, and 178 pages of expert insights, providing a complete view of the market landscape.